-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Invitation to the event2021 Oncolytic Virus Drug Development Forum will open in Shanghai ★ The financing has reached hundreds of millions in half a year, and the oncolytic virus has entered the fast laneYimai New Observation Click on the picture and register now May 28, 2021 /Healthcare News eMedClub News/--On May 27, 2021, Chongqing Precision Biotech Co.
, Ltd.
held a "Chimera" at the Hematology Hospital (Institute of Hematology) of the Chinese Academy of Medical Sciences.
Antigen receptor T lymphocyte (CAR-T) preparation (C-4-29) for the treatment of patients with relapsed/refractory multiple myeloma phase I clinical trial study kick-off meeting".
The registered clinical trial was conducted by Professor Hu Yu from the Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Professor Liu Ting from the Department of Hematology, West China Hospital, Sichuan University, and Professor An Gang from the Lymphoma Diagnosis and Treatment Center of the Hospital of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences Principal Investigator (PI).
At present, Chongqing Precision Biotechnology Co.
, Ltd.
has obtained the implied license for four clinical trials, covering multiple myeloma, childhood and adult leukemia, and lymphoma.
At the kick-off meeting of the Hematology Hospital of the Institute of Hematology, Chinese Academy of Medical Sciences, Mr.
Wei Siwen from the Office of Drug Clinical Trials, Professor An Gang from the Lymphoma Diagnosis and Treatment Center, and expert backbone doctors and nursing staff from the Lymphoma Diagnosis and Treatment Center attended the meeting.
Make valuable suggestions.
Discussions at the meeting were enthusiastic, and everyone actively spoke.
At the end of the meeting, Professor An Gang announced the official launch of the project and fully promoted the project.
About C-4-29 cell preparation The C-4-29 cell preparation independently developed by Chongqing Precision Biotechnology Co.
, Ltd.
is a brand-new dual-target CAR-T cell injection.
Its target combination is an international initiative.
This registration The clinical indication is "for the treatment of relapsed/refractory multiple myeloma ≥18 years of age".
C-4-29 cell preparations belong to the first class of new therapeutic biological products.
The product has been shown to have With good safety and effectiveness, as the first multi-target product targeting multiple myeloma, it is expected to further improve the clinical efficacy of tumor treatment and reduce the risk of tumor recurrence.
About Precision Biology Chongqing Precision Biology was established in 2016.
It is a high-tech enterprise jointly established by a technical team of well-known precision medicine scientist Professor Qian Cheng and Zhirui Investment under the listed company Zhifei Biology.
The company uses biological therapy (CAR-T).
, TCR-T, CAR-NK) and other technologies as entry points to carry out biomedicine research and development and transformation.
The company has established an industrial technology research institute and a post-doctoral workstation, and has been approved for platform qualifications such as Chongqing’s new high-end R&D institutions, cell therapy key laboratories, engineering research centers, and engineering technology research centers.
The company has built 20,000 square meters of domestic top-notch cell drug IND and NDA platforms with complete platforms and powerful functions in Chongqing High-tech Zone.
It has high-intelligent production lines and online testing platforms for plasmid, vector, and cell preparation; it brings together more than 20 international companies.
The first-class expert leader has formed a team of more than 250 R&D elites; through independent research and development, it has already possessed key core technologies in the field of biotherapy, and has made major breakthroughs in cutting-edge technology fields such as general-purpose CAR-T and microenvironment-induced CAR-T.
Applied for 57 core invention patents and obtained 14 core invention patent authorizations; the company's CAR-T cell therapy products have been successfully applied to leukemia, lymphoma, multiple myeloma, colorectal cancer, gastric cancer, lung cancer, breast cancer, and pancreatic cancer For the treatment of various tumors, the company has obtained implied licenses for two national Class I new biological drugs and four indications.
At present, the company is fully advancing the registration of clinical trials and is preparing to apply for CAR-T cell treatment of solid tumors IND. Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups.
, Ltd.
held a "Chimera" at the Hematology Hospital (Institute of Hematology) of the Chinese Academy of Medical Sciences.
Antigen receptor T lymphocyte (CAR-T) preparation (C-4-29) for the treatment of patients with relapsed/refractory multiple myeloma phase I clinical trial study kick-off meeting".
The registered clinical trial was conducted by Professor Hu Yu from the Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Professor Liu Ting from the Department of Hematology, West China Hospital, Sichuan University, and Professor An Gang from the Lymphoma Diagnosis and Treatment Center of the Hospital of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences Principal Investigator (PI).
At present, Chongqing Precision Biotechnology Co.
, Ltd.
has obtained the implied license for four clinical trials, covering multiple myeloma, childhood and adult leukemia, and lymphoma.
At the kick-off meeting of the Hematology Hospital of the Institute of Hematology, Chinese Academy of Medical Sciences, Mr.
Wei Siwen from the Office of Drug Clinical Trials, Professor An Gang from the Lymphoma Diagnosis and Treatment Center, and expert backbone doctors and nursing staff from the Lymphoma Diagnosis and Treatment Center attended the meeting.
Make valuable suggestions.
Discussions at the meeting were enthusiastic, and everyone actively spoke.
At the end of the meeting, Professor An Gang announced the official launch of the project and fully promoted the project.
About C-4-29 cell preparation The C-4-29 cell preparation independently developed by Chongqing Precision Biotechnology Co.
, Ltd.
is a brand-new dual-target CAR-T cell injection.
Its target combination is an international initiative.
This registration The clinical indication is "for the treatment of relapsed/refractory multiple myeloma ≥18 years of age".
C-4-29 cell preparations belong to the first class of new therapeutic biological products.
The product has been shown to have With good safety and effectiveness, as the first multi-target product targeting multiple myeloma, it is expected to further improve the clinical efficacy of tumor treatment and reduce the risk of tumor recurrence.
About Precision Biology Chongqing Precision Biology was established in 2016.
It is a high-tech enterprise jointly established by a technical team of well-known precision medicine scientist Professor Qian Cheng and Zhirui Investment under the listed company Zhifei Biology.
The company uses biological therapy (CAR-T).
, TCR-T, CAR-NK) and other technologies as entry points to carry out biomedicine research and development and transformation.
The company has established an industrial technology research institute and a post-doctoral workstation, and has been approved for platform qualifications such as Chongqing’s new high-end R&D institutions, cell therapy key laboratories, engineering research centers, and engineering technology research centers.
The company has built 20,000 square meters of domestic top-notch cell drug IND and NDA platforms with complete platforms and powerful functions in Chongqing High-tech Zone.
It has high-intelligent production lines and online testing platforms for plasmid, vector, and cell preparation; it brings together more than 20 international companies.
The first-class expert leader has formed a team of more than 250 R&D elites; through independent research and development, it has already possessed key core technologies in the field of biotherapy, and has made major breakthroughs in cutting-edge technology fields such as general-purpose CAR-T and microenvironment-induced CAR-T.
Applied for 57 core invention patents and obtained 14 core invention patent authorizations; the company's CAR-T cell therapy products have been successfully applied to leukemia, lymphoma, multiple myeloma, colorectal cancer, gastric cancer, lung cancer, breast cancer, and pancreatic cancer For the treatment of various tumors, the company has obtained implied licenses for two national Class I new biological drugs and four indications.
At present, the company is fully advancing the registration of clinical trials and is preparing to apply for CAR-T cell treatment of solid tumors IND. Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups.
